Search
Mifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalMDP is a motif present in all gram-positive and gram-negative bacterial walls that is recognized by different signalling molecules and activators such as nucleotide-binding and oligomerization domain ( … NOD)-like receptors (NLRs) and toll-like receptors present in macrophages and monocytes.
Amiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalAmiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
Synonyms: N-amidino-3,5-diamino-6-chloropyrazinecarboxamide, 3,5-diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamideMixtures: Nu-amilzide 5/50 Mg TabPlasma protein fraction (human)
go.drugbank.com/drugs/DB13968ApprovedInvestigationalThe composition of PPFh should be 5% of protein from which 83% should consist of albumin and no more of 17% should be globulin. … It is also stated that no more than 1% of the total protein should be gamma globulin.[L2260] PPFh is a sterile, frozen solution of solvent/detergent treated human plasma.
Products: OCTAPLAS Blood Group ONaftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum
Icatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … relief was observed to be 8 hours compared to 36 hours for the placebo treatment.
Categories: Analgesics, Non-NarcoticBupropion
go.drugbank.com/drugs/DB01156ApprovedInvestigational[A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved … [A178789] Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical
Paraldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigational[A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709] … [A232079] Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and so more selective modulators were developed.
Calfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalCalfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. … It adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant.
Anakinra
go.drugbank.com/drugs/DB00026ApprovedInvestigationalOn November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … [A247265] On November 8, 2022, the FDA issued an emergency use authorization (EUA) of anakinra for the treatment of COVID-19 in hospitalized patients who are at risk of progressing to severe respiratory